| Literature DB >> 32377535 |
Huiyong Peng1, Shuting Ren2, Yingzhao Liu3, Huimin Zhou4, Xinyi Tang1, Jun Yang1, Jie Tian4, Ping Xu5, Huaxi Xu4, Shengjun Wang1,4.
Abstract
Long noncoding RNAs (lncRNAs) have been increasingly recognized as key immune molecules that participate in the pathogenesis of autoimmune diseases. Previous studies have demonstrated that the lncRNA Ifng-AS1, a key scaffold that contributes to the transcription of IFN-γ, depends on T-bet for active transcription in Th1 cells. However, the effect of its human ortholog, IFNG-AS1, on the pathogenesis of rheumatoid arthritis (RA) remains unclear. In this study, we found that the transcript level of lncRNA IFNG-AS1 was increased in the peripheral blood of RA patients. IFNG, as a target gene of IFNG-AS1, was overexpressed and positively correlated with the transcript level of IFNG-AS1 in the RA patients. Our data also showed that the transcript level of T-bet was upregulated and positively correlated with IFNG-AS1 expression. T-bet regulated the transcription of IFNG-AS1 in human CD4+ T cells in vitro. Furthermore, strong positive correlations were observed between the increased transcript level of IFNG-AS1 and the serum level of rheumatoid factor, the erythrocyte sedimentation rate, and the C-reactive protein in RA patients, and patients positive for anticyclic citrullinated peptide antibodies had increased levels of IFNG-AS1. Finally, receiver operating characteristic (ROC) curve analysis suggested that IFNG-AS1 might be a potential biomarker of RA. Taken together, our findings indicated that IFNG-AS1, guided by T-bet, is augmented in the peripheral blood of RA patients and may play a critical role in the pathogenesis of RA by regulating the expression of IFNG.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32377535 PMCID: PMC7193778 DOI: 10.1155/2020/6401978
Source DB: PubMed Journal: J Immunol Res ISSN: 2314-7156 Impact factor: 4.818
Clinical features of the patients and the healthy controls included in the study.
| RA patients | OA patients | Healthy controls | Range | |
|---|---|---|---|---|
| Number | 31 | 8 | 30 | |
| Gender (M/F) | 8/23 | 2/6 | 6/24 | |
| Age (years) | 58 ± 16 | 60 ± 16 | 50 ± 20 | |
| RF (IU/mL) | 150 ± 153 | 8 ± 4 | 5 ± 3 | 0-20 |
| CRP (mg/L) | 19.1 ± 22.3 | 15.9 ± 26.2 | 0.78 ± 0.76 | 0-5 |
| ESR (mm/h) | 49 ± 31 | 17 ± 18 | 3 ± 1 | 0-20 |
| Anti-CCP-Ab (+/-) | 25/6 | — | — |
Primer sequences of the genes in the study.
| Primer ID | Nucleotide | Sequence (5′-3′) | |
|---|---|---|---|
| T-bet | NM_013351.2 | Forward | TTGAGGTGAACGACGGAGAG |
| Reverse | GGCATTCTGGTAGGCAGTCA | ||
|
| |||
| IFNG | NM_000619.3 | Forward | GAGTGTGGAGACCATCAAGGA |
| Reverse | TGTATTGCTTTGCGTTGGAC | ||
|
| |||
| IFNG-AS1 | NR_104125.1 | Forward | GCTGATGATGGTGGTGGCAATCT |
| Reverse | TTAGCAGTTGGTGGGCTTCT | ||
|
| |||
|
| NM_001101.5 | Forward | GAGTGTGGAGACCATCAAGGA |
| Reverse | TGTATTGCTTTGCGTTGGAC | ||
Figure 1Increased expression of IFNG-AS1 correlates with the clinical disease severity in the RA patients. (a) The transcript levels of IFNG-AS1 in the PBMCs from the RA patients and the healthy controls were detected by qRT-PCR. The correlations between the transcript level of IFNG-AS1 and the concentration of RF (b), the ESR (c), and the CRP level (d) in the RA patients are shown. (e) The relative expression of IFNG-AS1 in the PBMCs from the anti-CCP Ab- and anti-CCP-Ab+ RA patients was determined. Each data point represents an individual subject, and the horizontal lines show the mean. ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001.
Figure 2IFNG-AS1 expression positively correlates with the elevated level of IFNG in the RA patients. (a) The IFNG mRNA levels in the PBMCs from the RA patients, the OA patients, and the healthy controls were detected by qRT-PCR. (b) The correlation between the transcript level of IFNG-AS1 and the transcript level of IFNG in the RA patients is shown. (c) The correlation between the transcript level of IFNG-AS1 and the mRNA level of IFNG in the OA patients is shown. Each data point represents an individual subject, and the horizontal lines show the mean. ∗p < 0.05.
Figure 3Positive correlations between the elevated levels of T-bet and IFNG-AS1 in the RA patients. (a) The relative mRNA levels of T-bet in the PBMCs from the RA patients, the OA patients, and the healthy controls were detected by qRT-PCR. (b) The correlation between the transcript level of T-bet mRNA and the level of IFNG-AS1 in the RA patients is shown. (c) The correlation between T-bet mRNA expression and IFNG-AS1 expression in the OA patients is shown. Each data point represents an individual subject, and the horizontal lines show the mean. ∗p < 0.05.
Figure 4Effect of T-bet on IFNG-AS1 transcription in human CD4+ T cells. Human CD4+ T cells were purified from the PBMCs by magnetic beads and transfected with the T-bet-specific siRNA and the negative control (50 nM) in the presence of functional anti-human CD3 mAb and anti-human CD28 mAb to detect the transcript levels of T-bet mRNA and IFNG-AS1. (a) The mRNA level of T-bet was detected by qRT-PCR after transfection. (b) The mRNA level of T-bet was detected after transfection with the T-bet-specific siRNA in a dose-dependent manner. (c) The transcript level of IFNG-AS1 was detected by qRT-PCR after transfection. The results are shown as the mean ± SD of three independent experiments, and the horizontal lines show the mean. ∗∗∗p < 0.001.
Figure 5Potential diagnostic value of IFNG-AS1 in RA. ROC curve analysis using IFNG-AS1 to distinguish the RA patients was performed. ROC curve analysis was performed to show the AUC of IFNG-AS1.